Stockreport

Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata

Concert Pharmaceuticals, Inc.  (CNCE) 
Last concert pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.concertpharma.com/investor-relations
PDF LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the details of its pivotal Phase 3 trials of CTP-543 in patients with [Read more]